BACKGROUND AND PURPOSE: Gadobenate dimeglumine has proved advantageous compared with other gadolinium-based contrast agents for contrast-enhanced brain MR imaging. Gadobutrol is a more highly concentrated agent (1.0 mol/L). This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative evaluation of brain tumors. MATERIALS AND METHODS: Adult patients with suspected or known brain tumors underwent 2 identical MR imaging examinations at 1.5T, 1 with gadobenate dimeglumine and the other with gadobutrol, both at a dose of 0.1-mmol/kg body weight. The agents were injected in randomized order separated by 3-14 days. Imaging sequences and acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for CNR and LBR. RESULTS: One hundred fourteen of 123 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumors, metastases, extra-axial tumors, "other" tumors, and "nontumor" (49, 46, 8, 7, and 4 subjects, respectively). Readers 1, 2, and 3 demonstrated preference for gadobenate dimeglumine in 46 (40.7%), 54 (47.4%), and 49 (43.0%) patients, respectively, compared with 6, 7, and 7 patients for gadobutrol (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all other qualitative end points. Inter-reader agreement was good for all evaluations (κ = 0.414-0.629). Significantly superior CNR and LBR were determined for gadobenate dimeglumine (P < .019, all readers). CONCLUSIONS: Significantly greater morphologic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadobutrol at an equivalent dose.

Lekarska Fakulta Neurologicka Klinika Prague Czech Republic

Zobrazit více v PubMed

Colosimo C, Ruscalleda J, Korves M, et al. . Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 2001;36:72–81 PubMed

Knopp MV, Runge VM, Essig M, et al. . Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55–64 PubMed

Colosimo C, Knopp MV, Barreau X, et al. . A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655–65 PubMed

Essig M, Tartaro A, Tartaglione T, et al. . Enhancing lesions of the brain: intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 2006;13:744–51 PubMed

Maravilla KR, Maldjian JA, Schmalfuss IM, et al. . Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389–400 PubMed

Kuhn MJ, Picozzi P, Maldjian JA, et al. . Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557–66 PubMed

Rowley HA, Scialfa G, Gao PY, et al. . Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684–91 PubMed PMC

Rumboldt Z, Rowley HA, Steinberg F, et al. . Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760–67 PubMed PMC

MultiHance. Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/6132/SPC/multihance/#INDICATIONS. Accessed February 3, 2011

Pintaske J, Martirosian P, Graf H, et al. . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21. Erratum in Invest Radiol 2006;41:859 PubMed

Rohrer M, Bauer H, Mintorovitch J, et al. . Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715–24 PubMed

Cavagna FM, Maggioni F, Castelli PM, et al. . Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780–96 PubMed

Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. . Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222–28 PubMed

Gadavist (gadobutrol) injection. Bayer HealthCare Pharmaceuticals; March 2011. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=40544. Accessed February 3, 2012

Anzalone N, Gerevini S, Scotti R, et al. . Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009;50:933–40 PubMed

Kim ES, Chang JH, Choi HS, et al. . Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol 2010;31:1055–58 PubMed PMC

Katakami N, Inaba Y, Sugata S, et al. . Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011; 46:411–18 PubMed

Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York: John Wiley & Sons Inc; 1981

Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 2003;14:426–35 PubMed

Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128–37 PubMed

Yuh WT, Fisher DJ, Engelken JD, et al. . MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485–91 PubMed

Schneider G, Kirchin MA, Pirovano G, et al. . Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 2001;14:525–39 PubMed

Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009;24:3882–84. Epub 2009 Sep 19 PubMed

Elmholdt TR, Jørgensen B, Ramsing M, et al. . Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. Nephrol Dial Transplant 2010;3:285–87 PubMed PMC

Anzalone N. Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features. AJNR Am J Neuroradiol 2010;31:981–82 PubMed PMC

Achenbach M, Figiel JH, Burbelko M, et al. . Prospective comparison of image quality and diagnostic accuracy of 0.5 molar gadobenate dimeglumine and 1.0 molar gadobutrol in contrast-enhanced run-off magnetic resonance angiography of the lower extremities. J Magn Reson Imaging 2010;32:1166–71 PubMed

Grazioli L, Morana G, Kirchin MA, et al. . Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236:166–77 PubMed

Morana G, Grazioli L, Kirchin MA, et al. . Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011;46:225–39 PubMed

de Haën C, Cabrini M, Akhnana L, et al. . Gadobenate dimeglumine 0.5M solution for injection (MultiHance): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(suppl 1):S161–68 PubMed

Banci L, Bertini I, Luchinat C. Nuclear and Electron Relaxation. Weinheim, Germany: VCH Verlagsgesellschaft; 1991:138

Bültmann E, Erb G, Kirchin MA, et al. . Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol 2008;43:695–702 PubMed

Vogler H, Platzek J, Schuhmann-Giampieri G, et al. . Pre-clinical evaluation of gadobutrol: a new, neutral, extracellular contrast agent for magnetic resonance imaging. Eur J Radiol 1995;21:1–10 PubMed

Tombach B, Heindel W. Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol. Eur Radiol 2002;12:1550–56 PubMed

Gerretsen SC, le Maire TF, Miller S, et al. . Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010;255:988–1000 PubMed

Schneider G, Pasowicz M, Vymazal J, et al. . Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: multicenter intraindividual crossover comparison. AJR Am J Roentgenol 2010;195:476–85 PubMed

Martincich L, Faivre-Pierret M, Zechmann CM, et al. . Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT trial). Radiology 2011;258:396–408 PubMed

Heiland S, Erb G, Ziegler S, et al. . Where contrast agent concentration really matters: a comparison of CT and MRI. Invest Radiol 2010;45:529–37 PubMed

Comparison between postcontrast thin-slice T1-weighted 2D spin echo and 3D T1-weighted SPACE sequences in the detection of brain metastases at 1.5 and 3 T

Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine

The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)

Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study)